A cash dividend of 1.2p per ordinary share was paid in December 2022, in respect of the final dividend for 2021. In addition, the majority of the Group's investment in Verici Dx plc was transferred to shareholders by way of a dividend in specie in June 2022, at a value of £2.0m. EKF Diagnostics Holdings Plc can confirm that they intend to make a further dividend payment to shareholders of 1.2p per ordinary share in respect of the performance of the business in 2022. If approved by shareholders at the Company's next Annual General Meeting, payment of the dividend will be made on Friday 1 December 2023. The associated record date for this dividend is Friday 3 November 2023, and the ex-dividend date would be Thursday 2 November 2023.
Other FInancial Highlights:
- Revenues of £66.6m in-line with market expectations (2021: £81.8m)
- Gross profit before exceptionals of £30.8m (2021: £39.4m)
- Adjusted EBITDA of £14.9m (2021: £26.5m) (24% up from pre-pandemic levels (2019: £12.0m))
- Loss before tax of £8.9m (2021: £21.4m profit) after transition and restructuring costs of £17.5m
- Cash generated from operations of £12.7m (2021: £14.2m)
- Group cash, net of borrowings (excluding IFRS 16 liabilities), as at 31 December 2022 of £11.4m (31 December 2021: £19.6m), primarily reflecting cash generated from operations less £4.4m capital expenditure, £2.9m investments, £3.9m share buyback and £5.5m dividend payment
